In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.78 below Myriad Genetics Inc average.

Within In Vitro & In Vivo Diagnostic Substances industry 10 other companies have achieved higher Quick Ratio than Myriad Genetics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1675 to 2083.

Explain Quick Ratio?
How much Cash & cash equivalents MYGN�s has?
What are MYGN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MYGN/financial-strength

https://api.csimarket.com/api/v1/companies/MYGN/fundamentals

https://api.csimarket.com/api/v1/companies/MYGN/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

MYGN Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-7.03 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-26.34 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.78	Subscribe	Subscribe	Subscribe	Subscribe
MYGN's Total Ranking	# 2083	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	5.28 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-7.03 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 11
Healthcare Sector	# 650
Overall Market	# 2083

Quick Ratio Statistics
High	Average	Low
12.04	2.76	0.37
(Dec 31 2010)		(Jun 30 2025)

Financial Statements
Myriad Genetics Inc 's Current Liabilities	$ 138 Millions	Visit MYGN's Balance sheet
Myriad Genetics Inc 's Cash & cash equivalent	$ 107 Millions	Visit MYGN's Balance sheet
Source of MYGN's Sales		Visit MYGN's Sales by Geography

Cumulative Myriad Genetics Inc 's Quick Ratio

MYGN's Quick Ratio for the trailling 12 Months

MYGN Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-19.73 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	19.88 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.93	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1506	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-1.92 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-7.16 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to MYGN Financial Strength Comparisons >> Go to Compare MYGN Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in MYGN's Current Liabilities to $137.60 millions, cumulative Quick Ratio to 0.93 below the MYGN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Myriad Genetics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3130 to 3985.

Explain Quick Ratio?
How much Cash & cash equivalents MYGN�s has?
What are MYGN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 894
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.78	0.98	0.41
(Jun 30 2011)		(Sep 30 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Lantheus Holdings Inc	1.98	$ 683.610 Millions	$ 345.967 Millions
Alpha Teknova Inc	1.86	$ 16.560 Millions	$ 8.926 Millions
Immucell Corporation	1.23	$ 7.914 Millions	$ 6.460 Millions
Biomerica Inc	0.96	$ 2.733 Millions	$ 2.837 Millions
Myriad Genetics Inc	0.78	$ 107.100 Millions	$ 137.600 Millions
Volitionrx Limited	0.27	$ 2.400 Millions	$ 8.732 Millions
Neogen Corporation	0.19	$ 172.000 Millions	$ 899.100 Millions
Idexx Laboratories Inc	0.16	$ 197.536 Millions	$ 1,264.222 Millions
Quidelortho Corp	0.16	$ 166.400 Millions	$ 1,067.100 Millions

Date modified: 2026-11-07T13:15:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.